DiGeorge syndrome affects roughly 1 in every 2,000 to 4,000 live births, making it one of the most common chromosomal deletion disorders in humans. A population-based newborn screening study estimated a minimum prevalence of about 1 in 2,148 live births, which is higher than many older estimates suggested.1PubMed Central. Estimate of the contemporary live-birth prevalence of recurrent 22q11.2 deletions: a cross-sectional analysis from population-based newborn screening The true number is almost certainly higher still, because the condition is widely underdiagnosed and some people live into middle age without knowing they have it.
The Prevalence Is Probably Underestimated
Older textbooks often cite a prevalence of roughly 1 in 4,000 live births for DiGeorge syndrome. That figure came from clinical case series, where the syndrome was identified mainly through severe heart defects or obvious immune problems picked up in infancy. The problem is that milder cases slip through. When researchers screened a large population of newborns directly for the underlying genetic deletion rather than waiting for symptoms to appear, the rate jumped to about 1 in 2,148, with a confidence interval spanning roughly 1 in 1,300 to 1 in 4,000.1PubMed Central. Estimate of the contemporary live-birth prevalence of recurrent 22q11.2 deletions: a cross-sectional analysis from population-based newborn screening The gap between the old clinical estimate and the newer screening-based estimate tells us that a sizable fraction of affected people are never diagnosed in childhood.
A review of patients diagnosed later in life confirmed this pattern. The condition has such diverse clinical features and variable severity that many individuals are not identified until adulthood, sometimes after decades of unexplained health issues.2PubMed Central. Phenotype of patients with late diagnosis of 22q11 deletion: a review and retrospective study One case report described a woman diagnosed at age 44 after recurrent fainting episodes turned out to stem from a congenital heart defect she had never known about.3European Heart Journal – Case Reports. Late diagnosed DiGeorge syndrome in a 44-year-old female: a rare cause for recurrent syncopes in adulthood—a case report Stories like hers are not as unusual as you might expect.
What Causes the Syndrome
DiGeorge syndrome is caused by a missing stretch of DNA on chromosome 22, specifically at a location labeled 22q11.2. Most affected individuals are missing about 3 million base pairs of genetic code from one copy of that chromosome. This deletion happens spontaneously during the formation of sperm or egg cells in the vast majority of cases. About 90% of the time, neither parent carries the deletion; it is a new, random event. In the remaining roughly 10%, one parent has the deletion themselves, often without knowing it, and passes it on.
One gene within the deleted region stands out as especially important. Mouse studies showed that losing just one working copy of a gene called TBX1 is enough to cause abnormal development of the arteries that branch off the aorta, closely mirroring one of the hallmark heart defects seen in humans with the syndrome.4Nature. Tbx1 haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice When researchers knocked out both copies of TBX1 in mice, the animals developed a wide range of problems strikingly similar to those seen in humans: an underdeveloped thymus, missing parathyroid glands, heart outflow tract defects, abnormal facial structures, and cleft palate.5PubMed. DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1 TBX1 is considered a central driver of the syndrome, though it is not the whole story.
Why Two People with the Same Deletion Can Look So Different
One of the most striking things about DiGeorge syndrome is how differently it can present from one person to the next. Two siblings carrying the identical deletion can have completely different medical histories: one might need open-heart surgery as an infant while the other has only mild learning difficulties. This variability has puzzled researchers for decades.
Part of the explanation lies beyond the deleted region itself. Researchers have found that additional mutations in genes located outside the deletion contribute to some patients’ symptoms, a situation sometimes called a “dual diagnosis,” occurring in about 1% of cases. In other cases, losing one copy of the 22q11.2 region unmasks a recessive mutation on the remaining chromosome that would otherwise have been harmless. On top of that, some of the deleted genes regulate how other genes across the genome are switched on and off. Studies have identified distinctive patterns in small regulatory molecules called microRNAs and in chemical tags on DNA that differ between patients and healthy controls.6PubMed Central. Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors In short, the deletion sets off a cascade of effects that interact with the rest of a person’s genetic and regulatory makeup in unpredictable ways.
Heart Defects
Congenital heart disease is the feature that brings most infants with DiGeorge syndrome to medical attention. About three-quarters of patients with the 22q11.2 deletion have some form of heart defect.7PubMed Central. Clinical manifestations of Deletion 22q11.2 syndrome (DiGeorge/Velo-Cardio-Facial syndrome) The most common types involve the outflow tract of the heart, the region where blood leaves the heart to enter the major arteries. These include tetralogy of Fallot (the most frequent single defect), interrupted aortic arch, truncus arteriosus, and ventricular septal defects.
The link runs in the other direction too. Among patients with tetralogy of Fallot who were not already known to have a genetic syndrome, about 6-7% turned out to carry the 22q11.2 deletion when tested.8International Journal of Cardiology. Frequency of 22q11.2 microdeletion in sporadic non-syndromic tetralogy of Fallot cases Cardiologists increasingly screen for the deletion whenever they see certain heart defect patterns in newborns, because identifying the syndrome early changes how the child is monitored and treated going forward.
Immune Function
The thymus, a small organ behind the breastbone, is where immune cells called T cells mature and learn to fight infections. In DiGeorge syndrome the thymus can be underdeveloped or, in rare cases, completely absent. The practical result is a spectrum of immune problems that ranges from essentially normal immunity all the way to a severe deficiency resembling what is seen in children born without any functional immune system.9PubMed Central. Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia
Most people with the deletion fall on the milder end of this spectrum. In what is sometimes called “partial DiGeorge syndrome,” T cell counts are below normal but not dangerously low, and the immune system functions adequately for everyday life. A long-term study tracking T cell populations in these patients found that although counts were lower than in unaffected people, they were not severely depressed, and the cells responded normally when challenged.10Journal of Allergy and Clinical Immunology. Long-term assessment of T-cell populations in DiGeorge syndrome Children with the partial form tend to see their immune function improve somewhat over the first few years of life. The complete form, where the thymus is entirely absent, is a medical emergency requiring specialized treatment such as thymus transplantation, but it accounts for less than 1% of all 22q11.2 deletion cases.
Calcium, Hormones, and the Parathyroid Glands
The parathyroid glands, which help control calcium levels in the blood, develop from the same embryonic tissue that forms the thymus. When that tissue does not develop properly, low parathyroid hormone and low blood calcium can result. Hypoparathyroidism was actually the first hormonal problem recognized in DiGeorge syndrome and remains one of its most common endocrine features.11Genetics in Medicine. Endocrine aspects of the 22q11.2 deletion syndrome
Low calcium can cause muscle cramps, tingling, and seizures, and in infants it is sometimes the very first clue that something is wrong. A study of patients with confirmed hypocalcemia found that their parathyroid hormone levels at the time of the low calcium were inappropriately low rather than elevated, confirming the glands were not responding the way they should.12Genetics in Medicine. Parathyroid hormone reserve in 22q11.2 deletion syndrome The severity can fluctuate over a lifetime, with some people experiencing low calcium mainly during periods of physiological stress like puberty, pregnancy, or illness. Beyond calcium problems, thyroid disorders (both underactive and overactive) and growth hormone deficiency have also been documented in patients with the deletion.11Genetics in Medicine. Endocrine aspects of the 22q11.2 deletion syndrome
Mental Health and Neurodevelopmental Effects
If there is one aspect of DiGeorge syndrome that receives too little public attention, it is the psychiatric and neurodevelopmental side. Learning disabilities, cognitive differences, palate abnormalities leading to speech difficulties, and behavioral challenges are major features of the condition.13PubMed Central. Speech-Language Disorders in 22q11.2 Deletion Syndrome: Best Practices for Diagnosis and Management But the psychiatric burden goes further than that.
In a study of 100 individuals with the deletion, autism spectrum disorders and ADHD were diagnosed in 44 cases, and intellectual disability with or without other neurodevelopmental conditions was present in more than half.14Research in Developmental Disabilities. Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome Among adults, mood disorders affect roughly a quarter and anxiety disorders about one in six.15Clinical Psychopharmacology and Neuroscience. Psychiatric Comorbidities in Adults with DiGeorge Syndrome
The most studied psychiatric association is with psychotic disorders, particularly schizophrenia. Data from an international consortium found that psychotic disorders were present in about 41% of adults with the deletion who were over age 25.16PubMed Central. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome Looking at it from the other direction, roughly 1% of all people diagnosed with schizophrenia carry the 22q11.2 deletion, making it one of the strongest known single genetic risk factors for psychotic illness.17PubMed Central. Schizophrenia and 22q11.2 deletion syndrome This connection has made the syndrome a major focus of psychiatric genetics research.
How It Gets Diagnosed
Historically, DiGeorge syndrome was suspected on clinical grounds when a newborn presented with a heart defect, low calcium, and immune problems occurring together. The standard genetic test was a technique called FISH (fluorescence in situ hybridization), which looks for the deletion directly. FISH catches most typical deletions but can miss smaller or unusual ones. More advanced testing using microarray technology has picked up clinically suspected 22q11.2 deletions in about 8% of cases where FISH results were negative or inconclusive.18PubMed Central. SNP Microarray in FISH Negative Clinically Suspected 22q11.2 Microdeletion Syndrome Chromosomal microarray has increasingly replaced FISH as the first-line test because it catches a wider range of deletion sizes.
An unexpected route to early diagnosis has come through newborn screening for severe combined immunodeficiency. This screening measures a marker of T cell production called TRECs in dried blood spots. Babies with very low T cell counts get flagged, and some of those turn out to have DiGeorge syndrome rather than classic immunodeficiency.19PubMed Central. Identification of 22q11.2 Deletion Syndrome via Newborn Screening for Severe Combined Immunodeficiency In one study, about 19% of confirmed DiGeorge patients had abnormal TREC results at birth, and those babies tended to have more significant T cell problems and greater vulnerability to viral infections than those whose TRECs were normal.20PubMed. Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome The screening catches only the most immunologically affected fraction, not everyone with the deletion, but it is still identifying babies who might otherwise have gone undiagnosed for years.
It is also worth noting that some patients present with the full clinical picture of DiGeorge syndrome but have no detectable deletion on any genetic test. These “DiGeorge-like” cases, where the combination of heart defects, immune problems, and developmental delays is present without the expected chromosomal finding, remind clinicians that the diagnosis is ultimately a clinical one that genetics helps confirm rather than define.21PubMed Central. Clinical Phenotype of DiGeorge Syndrome with Negative Genetic Tests: A Case of DiGeorge-Like Syndrome?
Prenatal Testing
Noninvasive prenatal screening using cell-free fetal DNA in the mother’s blood can now test for 22q11.2 deletions alongside the more commonly screened chromosomal conditions. However, the accuracy varies considerably depending on the study and the technology used. One analysis of early clinical experience reported a positive predictive value of only 18%, meaning that more than four out of five high-risk results turned out to be false alarms.22PubMed Central. Clinical experience with single‐nucleotide polymorphism‐based non‐invasive prenatal screening for 22q11.2 deletion syndrome A separate study using a different platform reported a much higher positive predictive value of 93% for DiGeorge syndrome specifically.23Genetics in Medicine. Clinical utility of noninvasive prenatal screening for expanded chromosome disease syndromes The difference likely reflects improvements in the technology and varying patient populations. In practice, any positive prenatal screening result still requires confirmation through invasive diagnostic testing such as amniocentesis before any clinical decisions are made.
Life Expectancy and Long-Term Outlook
With modern cardiac surgery and improved medical management, most people with DiGeorge syndrome survive well into adulthood. But the condition does carry an increased risk of premature death. In a study tracking adults with the deletion over time, about 10% had died by the end of the follow-up period, at a median age of roughly 46 years.24Genetics in Medicine. All-cause mortality and survival in adults with 22q11.2 deletion syndrome The deletion itself and the presence of a major congenital heart defect were the two strongest independent predictors of early death. Cardiovascular causes accounted for about 71% of deaths, with sudden cardiac death making up a substantial proportion and occurring even in some individuals without major structural heart defects.24Genetics in Medicine. All-cause mortality and survival in adults with 22q11.2 deletion syndrome
An earlier study estimated survival to age 40 at about 90% and survival to age 50 at about 74%.25PubMed Central. Premature death in adults with 22q11.2 deletion syndrome Interestingly, there was no excess of cancer or coronary artery disease in those who died, which are the leading killers in the general population. The causes of death were dominated by complications of congenital heart disease and sudden cardiac events. This pattern means that adults with the syndrome need ongoing cardiac monitoring, including those whose childhood heart defects were surgically repaired and seemingly resolved.
The Many Names Problem
If you search for information about DiGeorge syndrome, you will quickly encounter a confusing tangle of names. DiGeorge syndrome, velocardiofacial syndrome, 22q11.2 deletion syndrome, conotruncal anomalies face syndrome, CATCH 22, and Sedlacková syndrome have all been used to describe the same underlying condition.26PubMed Central. Velo-cardio-facial syndrome: 30 Years of study The connection between these seemingly separate conditions was not recognized until 1990, when researchers showed that a child with classic DiGeorge anomaly and a father with velocardiofacial syndrome shared the same chromosomal deletion.27Progress in Pediatric Cardiology. Historical perspectives of velo-cardio-facial syndrome
The proliferation of names arose because different medical specialties each described the features they encountered most. Immunologists saw the thymus and immune problems and called it DiGeorge syndrome. Speech pathologists and plastic surgeons noticed the palate abnormalities and facial features and called it velocardiofacial syndrome. Cardiologists focused on the heart defects. Only after genetic testing became widespread in the 1990s did it become clear that all these clinical descriptions pointed to the same chromosomal deletion. Today, “22q11.2 deletion syndrome” is the preferred umbrella term in genetics, though “DiGeorge syndrome” remains the name most recognizable to the general public and is still widely used in clinical practice.
The Caregiver Burden
Living with or caring for someone with DiGeorge syndrome involves navigating a complex web of specialists: cardiologists, immunologists, endocrinologists, speech therapists, psychologists, and geneticists, sometimes all for the same child. A recent study examining quality of life among caregivers found that about 85% rated their physical quality of life below the general population average, and roughly 84% rated their social relationships the same way.28PubMed Central. The impact of 22q11.2 deletion syndrome on caregivers: assessing quality of life and burden Diagnostic delays compounded the strain. Caregivers who waited years for a diagnosis reported lower quality of life even after the diagnosis was finally made, likely because the period of uncertainty and fragmented care left lasting effects. Maintaining professional activity outside of caregiving was one of the few factors associated with better psychological well-being for caregivers.
These findings underscore why earlier diagnosis matters beyond the medical benefits to the patient. When a unifying genetic diagnosis is established, the care team can coordinate more effectively, families can access condition-specific support networks, and the exhausting diagnostic odyssey of visiting specialist after specialist without a connecting thread comes to an end. For a condition this common, the gap between how many people have it and how many know they have it remains one of the most actionable problems in clinical genetics.